Bases Neurobiológicas y Psicológicas de los Trastornos Mentales. Trastornos del Neurodesarrollo

van der Wee NJA; Bilderbeck, AC; Cabello, M; Ayuso-Mateos, JL; Saris IMJ; Giltay, EJ; Penninx, BWJH; Arango, C; Post, A; Porcelli, S.

Working definitions, subjective and objective assessments and experimental paradigms in a study exploring social withdrawal in schizophrenia and Alzheimer's disease

NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS. 2019; 97: 38-46 Nº de citas: 18 [doi:10.1016/j.neubiorev.2018.06.020]

Martinuzzi, E; Barbosa, S; Daoudlarian, D; Ali, WBH; Gilet, C; Fillatre, L; Khalfallah, O; Troudet, R; Jamain, S; Fond, G; Sommer, I; Leucht, S; Dazzan, P; McGuire, P; Arango, C; Diaz-Caneja, CM; Fleischhacker, W; Rujescu, D; Glenthoj, B; Winter, I; Kahn, RS; Yolken, R; Lewis, S; Drake, R; Davidovic, L; Leboyer, M; Glaichenhaus, N; Kahn, RS; van Rossum, IW; Leucht, S; McGuire, P; Lewis, SW; Leboyer, M; Arango, C; Dazzan, P; Drake, R; Heres, S; Diaz-Caneja, CM; Rujescu, D; Weiser, M; Galderisi, S; Glenthoj, B; Eijkemans, MJC; Fleischhacker, WW; Kapur, S; Sommer, IE; OPTiMiSE Study Grp.

Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study

Translational Psychiatry. 2019; 9: Nº de citas: 59 [doi:10.1038/s41398-018-0366-5]

Jaen-Moreno, MJ; Feu, N; Redondo-Ecija, J; Montiel, FJ; Gomez, C; del Pozo, GI; Alcala, JA; Gutierrez-Rojas, L; Balanza-Martinez, V; Chauca, GM; Carrion, L; Osuna, MI; Sanchez, MD; Caro, I; Ayora, M; Valdivia, F; Lopez, MS; Poyato, JM; Sarramea, F.

Smoking cessation opportunities in severe mental illness (tobacco intensive motivational and estimate risk TIMER): study protocol for a randomized controlled trial

Trials. 2019; 20: Nº de citas: 4 [doi:10.1186/s13063-018-3139-9]

Gonzalez-Penas, J; Costas, J; Villamayor, MJG; Xu, B.

Enrichment of rare genetic variants in astrocyte gene enriched co-expression modules altered in postmortem brain samples of schizophrenia

NEUROBIOLOGY OF DISEASE. 2019; 121: 305-314 Nº de citas: 9 [doi:10.1016/j.nbd.2018.10.013]

Diaz-Caneja, CM; Cervilla, JA; Haro, JM; Arango, C; de Portugal, E.

Cognition and functionality in delusional disorder

EUROPEAN PSYCHIATRY. 2019; 55: 52-60 Nº de citas: 17 [doi:10.1016/j.eurpsy.2018.09.010]

Fraguas, D; Diaz-Caneja, CM; Pina-Camacho, L; Umbricht, D; Arango, C.

Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis

SCHIZOPHRENIA BULLETIN. 2019; 45(1): 57-68 Nº de citas: 19 [doi:10.1093/schbul/sbx192]

Downs, J; Dean, H; Lechler, S; Sears, N; Patel, R; Shetty, H; Hotopf, M; Ford, T; Kyriakopoulos, M; Diaz-Caneja, CM; Arango, C; MacCabe, JH; Hayes, RD; Pina-Camacho, L.

Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure

SCHIZOPHRENIA BULLETIN. 2019; 45(1): 69-79 Nº de citas: 44 [doi:10.1093/schbul/sbx197]

Boloc, D; Gortat, A; Cheng-Zhang, JQ; Garcia-Cerro, S; Rodriguez, N; Parellada, M; Saiz-Ruiz, J; Cuesta, MJ; Gasso, P; Lafuente, A; Bernardo, M; Mas, S.

Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics

Translational Psychiatry. 2018; 8: 276-276 Nº de citas: 14 [doi:10.1038/s41398-018-0330-4]

Hoffmann, C; Stevens, J; Zong, SH; van Kruining, D; Saxena, A; Kucukali, CI; Tuzun, E; Yalcinkaya, N; De Hert, M; Gonzalez-Vioque, E; Arango, C; Lindstrom, J; De Beets, MH; Rutter, BPF; van Os, J; Molenaar, P; Losen, M; Martinez-Martinez, P.

Alpha7 acetylcholine receptor autoantibodies are rare in sera of patients diagnosed with schizophrenia or bipolar disorder

PLoS One. 2018; 13(12): Nº de citas: 12 [doi:10.1371/journal.pone.0208412]

Garcia-Cabeza, I; Diaz-Caneja, CM; Ovejero, M; de Portugal, E.

Adherence, insight and disability in paranoid schizophrenia

PSYCHIATRY RESEARCH. 2018; 270: 274-280 Nº de citas: 10 [doi:10.1016/j.psychres.2018.09.021]

Miguelez-Fernandez, C; de Leon, SJ; Baltasar-Tello, I; Penuelas-Calvo, I; Barrigon, ML; Capdevila, AS; Delgado-Gomez, D; Baca-Garcia, E; Carballo, JJ.

Evaluating attention-deficit/hyperactivity disorder using ecological momentary assessment: a systematic review.

ADHD-ATTENTION DEFICIT AND HYPERACTIVITY DISORDERS. 2018; 10(4): 247-265 Nº de citas: 11 [doi:10.1007/s12402-018-0261-1]

Amoretti, S; Cabrera, B; Torrent, C; Mezquida, G; Lobo, A; Gonzalez-Pinto, A; Parellada, M; Corripio, I; Vieta, E; de la Serna, E; Butjosa, A; Contreras, F; Sarro, S; Penades, R; Sanchez-Torres, AM; Cuesta, M; Bernardo, M; PEPsGrp.

Cognitive reserve as an outcome predictor: first-episode affective versus non-affective psychosis

ACTA PSYCHIATRICA SCANDINAVICA. 2018; 138(5): 441-455 Nº de citas: 67 [doi:10.1111/acps.12949]

Diaz-Caneja, CM; Moron-Nozaleda, MG; Vicente-Moreno, RP; Rodriguez-Toscano, E; Pina-Camacho, L; de la Serna, E; Sugranyes, G; Baeza, I; Romero, S; Sanchez-Gistau, V; Castro-Fornieles, J; Moreno, C; Moreno, D.

Temperament in child and adolescent offspring of patients with schizophrenia and bipolar disorder

EUROPEAN CHILD & ADOLESCENT PSYCHIATRY. 2018; 27(11): 1459-1471 Nº de citas: 11 [doi:10.1007/s00787-018-1135-y]

Szerman, N; Peris, L.

Precision Psychiatry and Dual Disorders

JOURNAL OF DUAL DIAGNOSIS. 2018; 14(4): 237-246 Nº de citas: 20 [doi:10.1080/15504263.2018.1512727]

Fiksinski, AM; Schneider, M; Murphy, CM; Armando, M; Vicari, S; Canyelles, JM; Gothelf, D; Eliez, S; Breetvelt, EJ; Arango, C; Vorstman, JAS.

Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome

AMERICAN JOURNAL OF MEDICAL GENETICS PART A. 2018; 176(10): 2182-2191 Nº de citas: 46 [doi:10.1002/ajmg.a.40387]

Kahn, RS; van Rossum, IW; Leucht, S; McGuire, P; Lewis, SW; Leboyer, M; Arango, C; Dazzan, P; Drake, R; Heres, S; Diaz-Caneja, CM; Rujescu, D; Weiser, M; Galderisi, S; Glenthoj, B; Eijkemans, MJC; Fleischhacker, WW; Kapur, S; Sommer, IE; OPTIMISE Study Grp.

Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

Lancet Psychiatry. 2018; 5(10): 797-807 Nº de citas: 150 [doi:10.1016/S2215-0366(18)30252-9]

Ballesteros, A; Sanchez-Torres, AM; Lopez-Ilundain, JM; Cabrera, B; Lobo, A; Gonzalez-Pinto, AM; Diaz-Caneja, C; Corripio, I; Vieta, E; la Serna, E; Bobes, J; Usall, J; Contreras, F; Lorente-Omenaca, R; Mezquida, G; Bernardo, M; Cuesta, MJ; PEPs Grp.

Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?

PSYCHOLOGICAL MEDICINE. 2018; 48(13): 2247-2256 Nº de citas: 47 [doi:10.1017/S0033291717003774]

Sanchez-Torres, AM; Moreno-Izco, L; Lorente-Omenaca, R; Cabrera, B; Lobo, A; Gonzalez-Pinto, AM; Merchan-Naranjo, J; Corripio, I; Vieta, E; de la Serna, E; Butjosa, A; Contreras, F; Sarro, S; Mezquida, G; Ribeiro, M; Bernardo, M; Cuesta, MJ; PEPs Grp.

Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study

EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE. 2018; 268(7): 699-711 Nº de citas: 26 [doi:10.1007/s00406-017-0857-z]